Parkinson Disease and Type 2 diabetes
For decades, a question has buzzed around the scientific community: are diabetes and Parkinson's disease interlinked, with the risk of Parkinson's increasing among patients with type 2 diabetes (T2DM)? A PubMed query search using the keywords "(Diabetes[Title/Abstract]) AND (Parkinson's[Title/Abstract])" yielded 2,406 results, indicating the intensity with which this question has been pursued over the years. However, this chase may have reached a turning point. A recent study published in the New England Journal of Medicine by Olivier Rascol et al. showed that a diabetes drug slowed the progression of motor issues associated with Parkinson's disease.
This phase 2, double-blind, randomized, placebo-controlled trial investigated whether a diabetes drug called Lixisenatide could slow the worsening of motor symptoms in people with early-stage Parkinson's disease. After one year of follow-up, the group receiving the treatment saw no worsening movement symptoms, while those on the placebo did.
While the results after one year are encouraging, with no decline in motor function for those taking the drug compared to a worsening in the placebo group, Parkinson's disease typically progresses slowly. Therefore, a longer follow-up period, ideally another year, is crucial to determining Lixisenatide's efficacy.
Find the article here:
https://lnkd.in/gECz9vvD
Comments
Post a Comment